Neogenomics (NEO) Cash & Current Investments (2010 - 2026)

Neogenomics (NEO) has reported Cash & Current Investments for 17 consecutive years, with $146.1 million the latest figure, recorded in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $146.1 million, down 59.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.1 million (down 59.19% YoY), and the FY2025 annual result was $159.6 million, down 58.74% from the prior year.
• Cash & Current Investments was $146.1 million for Q1 2026 at Neogenomics, down from $159.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $481.4 million in Q1 2022 and troughed at $146.1 million in Q1 2026.
• Average Cash & Current Investments over 5 years is $353.7 million, with a median of $387.9 million recorded in 2024.
• Year-over-year, Cash & Current Investments retreated 3.59% in 2024 and slumped 59.19% in 2026.
• Over 5 years, Cash & Current Investments stood at $438.0 million in 2022, then decreased by 5.2% to $415.2 million in 2023, then retreated by 6.83% to $386.8 million in 2024, then sank by 58.74% to $159.6 million in 2025, then declined by 8.44% to $146.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $146.1 million in Q1 2026, $159.6 million in Q4 2025, and $164.1 million in Q3 2025.